Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
Michelle L. O’Donoghue(Thrombolysis in Myocardial Infarction Study Group), Marc S. Sabatine(Brigham and Women's Hospital)
Cited by 930
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.2k